ArticleF1000Research2025
Expression of EBNA1 and miR-155 in Papillary Thyroid Carcinoma: A Case-Control Study in Iraqi Patients.
Article in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary thyroid carcinoma (PTC) represents the most prevalent form of thyroid malignancy worldwide, with increasing incidence rates observed across various populations. Epstein-Barr virus (EBV) has been implicated in numerous malignancies, with its encoded nuclear antigen 1 (EBNA1) proposed to modulate host gene expression, particularly microRNAs, in some of these contexts. MicroRNA-155 (miR-155) has emerged as a significant oncogenic regulator in various cancers. Objectives: This study was designed to investigate the expression of EBNA1 and miR-155 in PTC and their association with one another, and to evaluate the diagnostic value of miR-155 in Iraqi patients. Materials and Methods: A case-control study was conducted involving 100 histologically confirmed PTC patients and 100 nodular goiter controls recruited from Baghdad, Iraq, between March 2024 and August 2024. Expression levels of EBNA1 and miR-155 were quantified using quantitative real-time polymerase chain reaction (qRT-PCR); EBNA1 protein expression was additionally assessed by immunohistochemistry (IHC). Statistical analyses included correlation assessment and receiver operating characteristic (ROC) curve analysis. Results: EBNA1 IHC positivity was higher in PTC cases (82%) compared to controls (41%) (p < 0.001). Both miR-155 and EBNA1 mRNA expression levels were significantly elevated in PTC cases, with mean values of 5.38 ± 2.50 and 24.3 ± 11.96, respectively, compared to controls (1.51 ± 1.25 and 15.9 ± 19.20, p < 0.0001). However, correlation analysis between miR-155 and EBNA1 mRNA expression levels revealed a weak negative relationship (r = -0.031, p = 0.758). ROC analysis demonstrated excellent diagnostic performance of miR-155 with an area under the curve (AUC) of 0.927, sensitivity of 83%, and specificity of 87%. Conclusion: EBNA1 and miR-155 are each independently elevated in PTC compared with benign nodular goiter, but their expression levels do not correlate, indicating that these two markers should be interpreted as independent findings rather than evidence of a direct regulatory relationship. MiR-155 demonstrates strong potential as a diagnostic biomarker for PTC in Iraqi patients, warranting further validation in prospective, multi-center cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.